RxDoctor Payments DataLook up a doctor →

Ali Alsaadi, MD

Internal Medicine · Farmington Hills, MINPI 1912941477

Payments from drug & device makers

$483,235in general payments, 2019–2025

Across 463 payments — averaging $1043.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seqirus USA Inc$428K
  • AstraZeneca$44K
  • Ferring Pharmaceuticals AS$5K
  • Medtronic$694
  • Sunovion Pharmaceuticals Inc.$573
  • GSK$282
  • plus $5K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Seqirus USA Inc139$427,891
AstraZeneca17$44,188
Ferring Pharmaceuticals AS2$5,000
Medtronic(2 entities)5$694
Sunovion Pharmaceuticals Inc.33$573
GSK16$282
Merck16$260
Teva Pharmaceuticals USA, Inc.14$256
Johnson & Johnson16$246
Novartis14$233
Pfizer11$208
Exact Sciences10$207
AbbVie(2 entities)12$195
Sumitomo Pharma America, Inc.10$192
UCB, Inc.7$188
Otsuka America Pharmaceutical, Inc.8$168
Sanofi-aventis U.S. LLC7$152
Lilly USA, LLC9$146
E.r. Squibb & Sons, L.L.C.9$143
Acadia Pharmaceuticals Inc7$142
Nestle Healthcare Nutrition Inc.7$128
Neurocrine Biosciences, Inc.5$105
Boehringer Ingelheim5$104
Astellas Pharma US Inc5$95
Amgen5$92
Abbott5$92
Lundbeck LLC3$84
Insmed, Inc.4$82
Urovant Sciences Inc5$81
Bayer5$77
Dexcom, Inc.4$71
Indivior Inc.4$69
Eisai Inc.3$67
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$56
Global Blood Therapeutics, Inc.3$54
Biogen3$53
Aimmune Therapeutics, Inc.3$52
Novo Nordisk3$44
Axsome Therapeutics, Inc.2$40
Evoke Pharma, Inc.3$39
Integra Lifesciences Corporation1$30
Sun Pharmaceutical Industries Inc.2$29
Vanda Pharmaceuticals Inc.1$29
Kowa Pharmaceuticals America, Inc.2$28
Abiomed1$23
Sanofi Pasteur Inc.1$23
Mannkind Corporation1$22
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$22
Otsuka Pharmaceutical Development & Commercialization, Inc.1$21
Avanir Pharmaceuticals, Inc.1$20
Xeris Pharmaceuticals, Inc.1$19
Validus Pharmaceuticals LLC1$19
Neurelis, Inc.1$17
Ultragenyx Pharmaceutical Inc.1$17
Amarin Pharma, Inc.1$16
Lucid Diagnostics Inc.1$15
Aprecia Pharmaceuticals, LLC1$13
Takeda Pharmaceuticals U.S.A., Inc.1$11
Hikma Pharmaceuticals USA1$11

How this compares

$483,235 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan →

Medicare billing

Part B allowed, 2024
$864,661
Medicare patients
601
Services billed
8,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Farmington Hills

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →